Intuitive Surgical, Inc.
NASDAQ•ISRG
CEO: Dr. Gary S. Guthart Ph.D.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2000-06-16
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Contact Information
Market Cap
$170.20B
P/E (TTM)
59.6
57.7
Dividend Yield
--
52W High
$603.88
52W Low
$425.00
52W Range
Rank30Top 19.5%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$2.87B+18.76%
4-Quarter Trend
EPS
$2.24+16.67%
4-Quarter Trend
FCF
$730.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Growth Strong Total revenue reached $10.06 B USD, marking a 21% increase; Instruments revenue grew 19% to $6.02 B USD.
Procedure Volume Accelerates da Vinci procedures grew 18% to 3,153 K procedures; Ion procedures surged 51% to 144.1 K performed in 2025.
Operating Income Rises 25% Operating income increased 25% to $2.95 B USD; da Vinci installed base grew 12% to 11,106 systems.
Risk Factors
Competition Pressures Margins Highly competitive landscape risks customer choice shifting away from robotic procedures, potentially reducing revenue and customer base.
Tariff Costs Impact Gross Profit New tariffs increased 2025 cost of revenues by $63.0 M USD; product gross margin fell to 66.3% from 67.2%.
Regulatory and Legal Exposure Subject to complex FDA and foreign regulations; ongoing litigation risks concerning product liability and antitrust claims remain.
Outlook
Continued R&D Investment Expect substantial ongoing investments in product development initiatives; R&D expenses anticipated to increase further in future periods.
OUS Expansion Focus Phased launch of da Vinci 5 system continues in OUS markets; China sales remain subject to quotas and governance scrutiny.
System Demand Driven by Procedures Future system placements depend on procedure growth, though customers remain cautious regarding capital spending cycles.
Peer Comparison
Revenue (TTM)
$21.92B
$11.24B
$10.06B
Gross Margin (Latest Quarter)
67.9%
67.2%
66.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ISRG | $170.20B | 59.6 | 16.4% | 1.5% |
| BDX | $57.83B | 25.9 | 6.9% | 35.6% |
| RMD | $33.92B | 22.9 | 24.8% | 11.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.3%
Steady Growth
4Q Net Income CAGR
4.4%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 20, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data